Fundamental Analysis of EKSO BIONICS HOLDINGS INC(NASDAQ:EKSO) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to EKSO. EKSO was compared to 195 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of EKSO have multiple concerns. EKSO is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year EKSO has reported negative net income.

EKSO had a negative operating cash flow in the past year.

EKSO had negative earnings in each of the past 5 years.

EKSO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -52.58%, EKSO is doing worse than 69.74% of the companies in the same industry.

The Return On Equity of EKSO (-120.61%) is worse than 73.33% of its industry peers.

		Industry Rank	Sector Rank
ROA	-52.58%
ROE	-120.61%
ROIC	N/A

ROA(3y)-37.12%

ROA(5y)-48.71%

ROE(3y)-69.61%

ROE(5y)-148.91%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

EKSO has a Gross Margin (49.67%) which is in line with its industry peers.

EKSO's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for EKSO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	49.67%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.54%

GM growth 5Y5.48%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EKSO does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for EKSO has been increased compared to 1 year ago.

EKSO has more shares outstanding than it did 5 years ago.

The debt/assets ratio for EKSO is higher compared to a year ago.

2.2 Solvency

EKSO has an Altman-Z score of -11.35. This is a bad value and indicates that EKSO is not financially healthy and even has some risk of bankruptcy.

EKSO has a Altman-Z score of -11.35. This is in the lower half of the industry: EKSO underperforms 79.49% of its industry peers.

A Debt/Equity ratio of 0.38 indicates that EKSO is not too dependend on debt financing.

EKSO has a Debt to Equity ratio (0.38) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.38
Debt/FCF	N/A
Altman-Z	-11.35

ROIC/WACCN/A

WACC9.37%

2.3 Liquidity

EKSO has a Current Ratio of 2.49. This indicates that EKSO is financially healthy and has no problem in meeting its short term obligations.

EKSO's Current ratio of 2.49 is on the low side compared to the rest of the industry. EKSO is outperformed by 63.08% of its industry peers.

A Quick Ratio of 1.87 indicates that EKSO should not have too much problems paying its short term obligations.

EKSO has a Quick ratio of 1.87. This is in the lower half of the industry: EKSO underperforms 60.51% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.49
Quick Ratio	1.87

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EKSO shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.17%.

The Revenue has grown by 41.46% in the past year. This is a very strong growth!

EKSO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.04% yearly.

EPS 1Y (TTM)5.17%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q8.33%

Revenue 1Y (TTM)41.46%

Revenue growth 3Y27.21%

Revenue growth 5Y10.04%

Revenue growth Q2Q36.54%

3.2 Future

EKSO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.80% yearly.

EKSO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.09% yearly.

EPS Next Y54.56%

EPS Next 2Y33.32%

EPS Next 3Y25.8%

EPS Next 5YN/A

Revenue Next Year29.09%

Revenue Next 2Y29.43%

Revenue Next 3Y29.09%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EKSO. In the last year negative earnings were reported.

Also next year EKSO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as EKSO's earnings are expected to grow with 25.80% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y33.32%

EPS Next 3Y25.8%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

EKSO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EKSO BIONICS HOLDINGS INC

NASDAQ:EKSO (4/26/2024, 7:00:02 PM)

1.25

-0.03 (-2.34%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap22.38M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-52.58%
ROE	-120.61%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	49.67%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.63

Health

		Industry Rank	Sector Rank
Debt/Equity	0.38
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.49
Quick Ratio	1.87
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)5.17%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y54.56%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)41.46%

Revenue growth 3Y27.21%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

EKSO BIONICS HOLDINGS INC (EKSO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens